Trial Outcomes & Findings for Study of Oral Edaravone in Healthy Adult Males (NCT NCT04481750)

Results Overview

Recruitment status

COMPLETED

Study phase

PHASE1

Target enrollment

74 participants

Primary outcome timeframe

Day 1 to 8 in Part 1, up to 12 days in Part 2

Results posted on

2026-01-07

Participant Flow

Participant milestones

Participant milestones
Measure	A Single Dose MT-1186 (Part 1, Cohort S1) Healthy Japanese male subjects receive a single dose of MT-1186 60 mg solution.	A Single Dose MT-1186 (Part 1, Cohort S2) Healthy Japanese male subjects receive a single dose of MT-1186 120 mg suspension.	A Single Dose MT-1186 (Part 1, Cohort S3) Healthy Japanese male subjects receive a single dose of MT-1186 200 mg under fasted condition in period 1, and fed condition in period 2 with washout period at least 4-day.	A Single Dose MT-1186 (Part 1, Cohort S4) Healthy Japanese male subjects receive a single dose of MT-1186 300 mg suspension with xanthan.	A Single Dose MT-1186 (Part 1, Cohort S5) Healthy Japanese male subjects receive a single dose of MT-1186 300 mg suspension.	A Single Dose MT-1186 (Part 1, Cohort S6) Healthy Japanese male subjects receive a single dose of MT-1186 30 mg suspension.	A Single Dose MT-1186 (Part 1, Cohort S7) Healthy Caucasian male subjects receive a single dose of MT-1186 200 mg suspension.	Matching Placebo (a Single Dose Cohorts) Healthy Japanese/Caucasian male subjects receive a single dose of matching placebo.	Multiple Doses MT-1186 (Part 2, Cohort M1) Healthy Japanese male subjects receive multiple doses of MT-1186 120 mg suspension.	Multiple Doses MT-1186 (Part 2, Cohort M2) Healthy Japanese male subjects receive multiple doses of MT-1186 200 mg suspension.	Matching Placebo (Multiple Doses Cohorts) Healthy Japanese male subjects receive multiple doses of matching placebo.
Period 1 (Fasted) STARTED	6	6	6	6	6	6	6	14	6	6	6
Period 1 (Fasted) COMPLETED	6	6	5	6	6	6	6	14	6	6	6
Period 1 (Fasted) NOT COMPLETED	0	0	1	0	0	0	0	0	0	0	0
Period 2 (After Meal) STARTED	0	0	5	0	0	0	0	0	0	0	0
Period 2 (After Meal) COMPLETED	0	0	5	0	0	0	0	0	0	0	0
Period 2 (After Meal) NOT COMPLETED	0	0	0	0	0	0	0	0	0	0	0

Reasons for withdrawal

Reasons for withdrawal
Measure	A Single Dose MT-1186 (Part 1, Cohort S1) Healthy Japanese male subjects receive a single dose of MT-1186 60 mg solution.	A Single Dose MT-1186 (Part 1, Cohort S2) Healthy Japanese male subjects receive a single dose of MT-1186 120 mg suspension.	A Single Dose MT-1186 (Part 1, Cohort S3) Healthy Japanese male subjects receive a single dose of MT-1186 200 mg under fasted condition in period 1, and fed condition in period 2 with washout period at least 4-day.	A Single Dose MT-1186 (Part 1, Cohort S4) Healthy Japanese male subjects receive a single dose of MT-1186 300 mg suspension with xanthan.	A Single Dose MT-1186 (Part 1, Cohort S5) Healthy Japanese male subjects receive a single dose of MT-1186 300 mg suspension.	A Single Dose MT-1186 (Part 1, Cohort S6) Healthy Japanese male subjects receive a single dose of MT-1186 30 mg suspension.	A Single Dose MT-1186 (Part 1, Cohort S7) Healthy Caucasian male subjects receive a single dose of MT-1186 200 mg suspension.	Matching Placebo (a Single Dose Cohorts) Healthy Japanese/Caucasian male subjects receive a single dose of matching placebo.	Multiple Doses MT-1186 (Part 2, Cohort M1) Healthy Japanese male subjects receive multiple doses of MT-1186 120 mg suspension.	Multiple Doses MT-1186 (Part 2, Cohort M2) Healthy Japanese male subjects receive multiple doses of MT-1186 200 mg suspension.	Matching Placebo (Multiple Doses Cohorts) Healthy Japanese male subjects receive multiple doses of matching placebo.
Period 1 (Fasted) Adverse Event	0	0	1	0	0	0	0	0	0	0	0

Baseline Characteristics

Study of Oral Edaravone in Healthy Adult Males

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	A Single Dose MT-1186 (Part 1, Cohort S1) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 60 mg solution.	A Single Dose MT-1186 (Part 1, Cohort S2) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 120 mg suspension.	A Single Dose MT-1186 (Part 1, Cohort S3) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 200 mg under fasted condition in period 1, and fed condition in period 2 with washout period at least 4-day.	A Single Dose MT-1186 (Part 1, Cohort S4) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 300 mg suspension with xanthan.	A Single Dose MT-1186 (Part 1, Cohort S5) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 300 mg suspension.	A Single Dose MT-1186 (Part 1, Cohort S6) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 30 mg suspension.	A Single Dose MT-1186 (Part 1, Cohort S7) n=6 Participants Healthy Caucasian male subjects receive a single dose of MT-1186 200 mg suspension.	Matching Placebo (a Single Dose Cohorts) n=14 Participants Healthy Japanese/Caucasian male subjects receive a single dose of matching placebo.	Multiple Doses MT-1186 (Part 2, Cohort M1) n=6 Participants Healthy Japanese male subjects receive multiple doses of MT-1186 120 mg suspension.	Multiple Doses MT-1186 (Part 2, Cohort M2) n=6 Participants Healthy Japanese male subjects receive multiple doses of MT-1186 200 mg suspension.	Matching Placebo (Multiple Doses Cohorts) n=6 Participants Healthy Japanese male subjects receive multiple doses of matching placebo.	Total n=74 Participants Total of all reporting groups
Age, Categorical <=18 years	0 Participants n=37 Participants	0 Participants n=56 Participants	0 Participants n=95 Participants	0 Participants n=61 Participants	0 Participants n=5 Participants	0 Participants n=25 Participants	0 Participants n=30 Participants	0 Participants n=82 Participants	0 Participants n=80 Participants	0 Participants n=81 Participants	0 Participants n=81 Participants	0 Participants n=80 Participants
Age, Categorical Between 18 and 65 years	6 Participants n=37 Participants	6 Participants n=56 Participants	6 Participants n=95 Participants	6 Participants n=61 Participants	6 Participants n=5 Participants	6 Participants n=25 Participants	6 Participants n=30 Participants	14 Participants n=82 Participants	6 Participants n=80 Participants	6 Participants n=81 Participants	6 Participants n=81 Participants	74 Participants n=80 Participants
Age, Categorical >=65 years	0 Participants n=37 Participants	0 Participants n=56 Participants	0 Participants n=95 Participants	0 Participants n=61 Participants	0 Participants n=5 Participants	0 Participants n=25 Participants	0 Participants n=30 Participants	0 Participants n=82 Participants	0 Participants n=80 Participants	0 Participants n=81 Participants	0 Participants n=81 Participants	0 Participants n=80 Participants
Sex: Female, Male Female	0 Participants n=37 Participants	0 Participants n=56 Participants	0 Participants n=95 Participants	0 Participants n=61 Participants	0 Participants n=5 Participants	0 Participants n=25 Participants	0 Participants n=30 Participants	0 Participants n=82 Participants	0 Participants n=80 Participants	0 Participants n=81 Participants	0 Participants n=81 Participants	0 Participants n=80 Participants
Sex: Female, Male Male	6 Participants n=37 Participants	6 Participants n=56 Participants	6 Participants n=95 Participants	6 Participants n=61 Participants	6 Participants n=5 Participants	6 Participants n=25 Participants	6 Participants n=30 Participants	14 Participants n=82 Participants	6 Participants n=80 Participants	6 Participants n=81 Participants	6 Participants n=81 Participants	74 Participants n=80 Participants
Race/Ethnicity, Customized White	0 Participants n=37 Participants	0 Participants n=56 Participants	0 Participants n=95 Participants	0 Participants n=61 Participants	0 Participants n=5 Participants	0 Participants n=25 Participants	6 Participants n=30 Participants	2 Participants n=82 Participants	0 Participants n=80 Participants	0 Participants n=81 Participants	0 Participants n=81 Participants	8 Participants n=80 Participants
Race/Ethnicity, Customized Asian (Japanese)	6 Participants n=37 Participants	6 Participants n=56 Participants	6 Participants n=95 Participants	6 Participants n=61 Participants	6 Participants n=5 Participants	6 Participants n=25 Participants	0 Participants n=30 Participants	12 Participants n=82 Participants	6 Participants n=80 Participants	6 Participants n=81 Participants	6 Participants n=81 Participants	66 Participants n=80 Participants

PRIMARY outcome

Timeframe: Day 1 to 8 in Part 1, up to 12 days in Part 2

Population: The trial is divided into 2 phases (a single and multiple-dose). A single-dose study included 8 cohorts (total of 56 subjects), with 42 (6x7) subjects receiving MT-1186, and 14 (2x7) receiving the placebo. Multiple-dose study included 2 cohorts (total of 18 subjects), with 12 (6x2) receiving MT-1186, and 6 (3x2) receiving the placebo for 5 days. Since Cohort S3-1 and S3-2 are crossover cohort, the 5 subjects in Cohort S3-2 are overlapped (total of 79 subjects).

Outcome measures

Outcome measures
Measure	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 60 mg solution under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 120 mg suspension under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 200 mg with fasted condition under period 1.	A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2) n=5 Participants Healthy Japanese male subjects receive a single dose of MT-1186 200 mg under fed condition in period 2 with washout period at least 4-day.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 300 mg suspension with xanthan under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 300 mg suspension under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 30 mg solution under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7) n=6 Participants Healthy Caucasian male subjects receive a single dose of MT-1186 200 mg suspension under fasted condition.	Matching Placebo Under Fasted Condition (a Sngle Dose Cohorts) n=14 Participants Healthy Japanese/Caucasian male subjects receive a single dose of matching placebo.	Multiple Doses MT-1186 (Part 2, Cohort M1) n=6 Participants Healthy Japanese male subjects receive multiple doses of MT-1186 120 mg suspension under fasted condition.	Multiple Doses MT-1186 (Part 2, Cohort M2) n=6 Participants Healthy Japanese male subjects receive multiple doses of MT-1186 200 mg suspension under fasted condition.	Matching Placebo (Multiple Doses Cohorts) n=6 Participants Healthy Japanese male subjects receive multiple doses of matching placebo under fasted condition.
Number of Participants With Adverse Events (Aes) and Adverse Drug Reactions (ADRs) Participants with AEs	0 Participants	2 Participants	3 Participants	0 Participants	0 Participants	1 Participants	1 Participants	2 Participants	2 Participants	2 Participants	1 Participants	1 Participants
Number of Participants With Adverse Events (Aes) and Adverse Drug Reactions (ADRs) Participants with ADRs	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants

PRIMARY outcome

Timeframe: Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5

Population: The trial is divided into 2 phases (a single and multiple-dose). A single-dose study included 8 cohorts (total of 56 subjects), with 42 (6x7) subjects receiving MT-1186, and 14 (2x7) receiving the placebo. Multiple-dose study included 2 cohorts (total of 18 subjects), with 12 (6x2) receiving MT-1186, and 6 (3x2) receiving the placebo for 5 days. Since Cohort S3-1 and S3-2 are crossover cohort, the 5 subjects in Cohort S3-2 are overlapped (59 patients receiving MT-1186).

Area under the plasma concentration versus time curve from time zero up to 24 hours (AUC0-24) of unchanged edaravone.

Outcome measures

Outcome measures
Measure	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 60 mg solution under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 120 mg suspension under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 200 mg with fasted condition under period 1.	A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2) n=5 Participants Healthy Japanese male subjects receive a single dose of MT-1186 200 mg under fed condition in period 2 with washout period at least 4-day.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 300 mg suspension with xanthan under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 300 mg suspension under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 30 mg solution under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7) n=6 Participants Healthy Caucasian male subjects receive a single dose of MT-1186 200 mg suspension under fasted condition.	Matching Placebo Under Fasted Condition (a Sngle Dose Cohorts) n=6 Participants Healthy Japanese/Caucasian male subjects receive a single dose of matching placebo.	Multiple Doses MT-1186 (Part 2, Cohort M1) n=6 Participants Healthy Japanese male subjects receive multiple doses of MT-1186 120 mg suspension under fasted condition.	Multiple Doses MT-1186 (Part 2, Cohort M2) Healthy Japanese male subjects receive multiple doses of MT-1186 200 mg suspension under fasted condition.	Matching Placebo (Multiple Doses Cohorts) Healthy Japanese male subjects receive multiple doses of matching placebo under fasted condition.
Area Under the Concentration Versus Time Curve (AUC) of Unchanged Edaravone AUC from time zero to 24 hour (AUC 0-24): Day 1	816 ng*h/mL Standard Deviation 231	2242 ng*h/mL Standard Deviation 911	6254 ng*h/mL Standard Deviation 1236	2443 ng*h/mL Standard Deviation 813	11319 ng*h/mL Standard Deviation 1053	9034 ng*h/mL Standard Deviation 2738	285 ng*h/mL Standard Deviation 113	4935 ng*h/mL Standard Deviation 1980	1917 ng*h/mL Standard Deviation 383	4133 ng*h/mL Standard Deviation 1260	—	—
Area Under the Concentration Versus Time Curve (AUC) of Unchanged Edaravone AUC from time zero to 24 hour (AUC 0-24): Day 5, only Part 2	—	—	—	—	—	—	—	—	2189 ng*h/mL Standard Deviation 516	4279 ng*h/mL Standard Deviation 1166	—	—

PRIMARY outcome

Timeframe: Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5

Population: The trial is divided into 2 phases (a single and multiple-dose). A single-dose study included 8 cohorts (total of 56 subjects), with 42 (6x7) subjects receiving MT-1186, and 14 (2x7) receiving the placebo. Multiple-dose study included 2 cohorts (total of 18 subjects), with 12 (6x2) receiving MT-1186, and 6 (3x2) receiving the placebo for 5 days. Since Cohort S3-1 and S3-2 are crossover cohort, the 5 subjects in Cohort S3-2 are overlapped (59 patients receiving MT-1186).

Area under the plasma concentration versus time curve from time zero up to 24 hours (AUC0-24) of sulfate conjugate.

Outcome measures

Outcome measures
Measure	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 60 mg solution under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 120 mg suspension under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 200 mg with fasted condition under period 1.	A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2) n=5 Participants Healthy Japanese male subjects receive a single dose of MT-1186 200 mg under fed condition in period 2 with washout period at least 4-day.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 300 mg suspension with xanthan under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 300 mg suspension under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 30 mg solution under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7) n=6 Participants Healthy Caucasian male subjects receive a single dose of MT-1186 200 mg suspension under fasted condition.	Matching Placebo Under Fasted Condition (a Sngle Dose Cohorts) n=6 Participants Healthy Japanese/Caucasian male subjects receive a single dose of matching placebo.	Multiple Doses MT-1186 (Part 2, Cohort M1) n=6 Participants Healthy Japanese male subjects receive multiple doses of MT-1186 120 mg suspension under fasted condition.	Multiple Doses MT-1186 (Part 2, Cohort M2) Healthy Japanese male subjects receive multiple doses of MT-1186 200 mg suspension under fasted condition.	Matching Placebo (Multiple Doses Cohorts) Healthy Japanese male subjects receive multiple doses of matching placebo under fasted condition.
Area Under the Concentration Versus Time Curve (AUC) of Sulfate Conjugate AUC from time zero to 24 hour (AUC 0-24): Day 1	16251 ng*h/mL Standard Deviation 7143	30004 ng*h/mL Standard Deviation 6103	45666 ng*h/mL Standard Deviation 10447	38244 ng*h/mL Standard Deviation 4602	67693 ng*h/mL Standard Deviation 14170	68126 ng*h/mL Standard Deviation 15067	6709 ng*h/mL Standard Deviation 2171	44797 ng*h/mL Standard Deviation 16374	26132 ng*h/mL Standard Deviation 4083	39516 ng*h/mL Standard Deviation 3331	—	—
Area Under the Concentration Versus Time Curve (AUC) of Sulfate Conjugate AUC from time zero to 24 hour (AUC 0-24): Day 5, only part 2	—	—	—	—	—	—	—	—	24578 ng*h/mL Standard Deviation 4186	39102 ng*h/mL Standard Deviation 4208	—	—

PRIMARY outcome

Timeframe: Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5

Population: The trial is divided into 2 phases (a single and multiple-dose). A single-dose study included 8 cohorts (total of 56 subjects), with 42 (6x7) subjects receiving MT-1186, and 14 (2x7) receiving the placebo. Multiple-dose study included 2 cohorts (total of 18 subjects), with 12 (6x2) receiving MT-1186, and 6 (3x2) receiving the placebo for 5 days. Since Cohort S3-1 and S3-2 are crossover cohort, the 5 subjects in Cohort S3-2 are overlapped (59 patients receiving MT-1186).

Area under the plasma concentration versus time curve from time zero up to 24 hours (AUC0-24) of glucuronide conjugate.

Outcome measures

Outcome measures
Measure	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 60 mg solution under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 120 mg suspension under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 200 mg with fasted condition under period 1.	A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2) n=5 Participants Healthy Japanese male subjects receive a single dose of MT-1186 200 mg under fed condition in period 2 with washout period at least 4-day.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 300 mg suspension with xanthan under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 300 mg suspension under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 30 mg solution under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7) n=6 Participants Healthy Caucasian male subjects receive a single dose of MT-1186 200 mg suspension under fasted condition.	Matching Placebo Under Fasted Condition (a Sngle Dose Cohorts) n=6 Participants Healthy Japanese/Caucasian male subjects receive a single dose of matching placebo.	Multiple Doses MT-1186 (Part 2, Cohort M1) n=6 Participants Healthy Japanese male subjects receive multiple doses of MT-1186 120 mg suspension under fasted condition.	Multiple Doses MT-1186 (Part 2, Cohort M2) Healthy Japanese male subjects receive multiple doses of MT-1186 200 mg suspension under fasted condition.	Matching Placebo (Multiple Doses Cohorts) Healthy Japanese male subjects receive multiple doses of matching placebo under fasted condition.
Area Under the Concentration Versus Time Curve (AUC) of Glucuronide Conjugate AUC from time zero to 24 hour (AUC 0-24):Day 1	2360 ng*h/mL Standard Deviation 648	4815 ng*h/mL Standard Deviation 910	8146 ng*h/mL Standard Deviation 1275	7406 ng*h/mL Standard Deviation 1368	14403 ng*h/mL Standard Deviation 1557	12499 ng*h/mL Standard Deviation 3457	1201 ng*h/mL Standard Deviation 454	8038 ng*h/mL Standard Deviation 1898	4806 ng*h/mL Standard Deviation 509	7932 ng*h/mL Standard Deviation 1190	—	—
Area Under the Concentration Versus Time Curve (AUC) of Glucuronide Conjugate AUC from time zero to 24 hour (AUC 0-24): Day 5, only part 2	—	—	—	—	—	—	—	—	4698 ng*h/mL Standard Deviation 499	8059 ng*h/mL Standard Deviation 1278	—	—

PRIMARY outcome

Timeframe: Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5

Population: The trial is divided into 2 phases (a single and multiple-dose). A single-dose study included 8 cohorts (total of 56 subjects), with 42 (6x7) subjects receiving MT-1186, and 14 (2x7) receiving the placebo. Multiple-dose study included 2 cohorts (total of 18 subjects), with 12 (6x2) receiving MT-1186, and 6 (3x2) receiving the placebo for 5 days. Since Cohort S3-1 and S3-2 are crossover cohort, the 5 subjects in Cohort S3-2 are overlapped (59 patients receiving MT-1186).

Outcome measures

Outcome measures
Measure	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 60 mg solution under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 120 mg suspension under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 200 mg with fasted condition under period 1.	A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2) n=5 Participants Healthy Japanese male subjects receive a single dose of MT-1186 200 mg under fed condition in period 2 with washout period at least 4-day.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 300 mg suspension with xanthan under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 300 mg suspension under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 30 mg solution under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7) n=6 Participants Healthy Caucasian male subjects receive a single dose of MT-1186 200 mg suspension under fasted condition.	Matching Placebo Under Fasted Condition (a Sngle Dose Cohorts) n=6 Participants Healthy Japanese/Caucasian male subjects receive a single dose of matching placebo.	Multiple Doses MT-1186 (Part 2, Cohort M1) n=6 Participants Healthy Japanese male subjects receive multiple doses of MT-1186 120 mg suspension under fasted condition.	Multiple Doses MT-1186 (Part 2, Cohort M2) Healthy Japanese male subjects receive multiple doses of MT-1186 200 mg suspension under fasted condition.	Matching Placebo (Multiple Doses Cohorts) Healthy Japanese male subjects receive multiple doses of matching placebo under fasted condition.
Maximum Plasma Concentration (Cmax) of Unchanged Edaravone Day 1	755 ng/mL Standard Deviation 356	1735 ng/mL Standard Deviation 738	4933 ng/mL Standard Deviation 1268	899 ng/mL Standard Deviation 464	8805 ng/mL Standard Deviation 933	5426 ng/mL Standard Deviation 2496	208 ng/mL Standard Deviation 112	3692 ng/mL Standard Deviation 1529	1953 ng/mL Standard Deviation 838	3855 ng/mL Standard Deviation 1676	—	—
Maximum Plasma Concentration (Cmax) of Unchanged Edaravone Day 5	—	—	—	—	—	—	—	—	2308 ng/mL Standard Deviation 941	4092 ng/mL Standard Deviation 1715	—	—

PRIMARY outcome

Timeframe: Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5

Population: The trial is divided into 2 phases (a single and multiple-dose). A single-dose study included 8 cohorts (total of 56 subjects), with 42 (6x7) subjects receiving MT-1186, and 14 (2x7) receiving the placebo. Multiple-dose study included 2 cohorts (total of 18 subjects), with 12 (6x2) receiving MT-1186, and 6 (3x2) receiving the placebo for 5 days. Since Cohort S3-1 and S3-2 are crossover cohort, the 5 subjects in Cohort S3-2 are overlapped (59 patients receiving MT-1186).

Outcome measures

Outcome measures
Measure	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 60 mg solution under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 120 mg suspension under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 200 mg with fasted condition under period 1.	A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2) n=5 Participants Healthy Japanese male subjects receive a single dose of MT-1186 200 mg under fed condition in period 2 with washout period at least 4-day.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 300 mg suspension with xanthan under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 300 mg suspension under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 30 mg solution under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7) n=6 Participants Healthy Caucasian male subjects receive a single dose of MT-1186 200 mg suspension under fasted condition.	Matching Placebo Under Fasted Condition (a Sngle Dose Cohorts) n=6 Participants Healthy Japanese/Caucasian male subjects receive a single dose of matching placebo.	Multiple Doses MT-1186 (Part 2, Cohort M1) n=6 Participants Healthy Japanese male subjects receive multiple doses of MT-1186 120 mg suspension under fasted condition.	Multiple Doses MT-1186 (Part 2, Cohort M2) Healthy Japanese male subjects receive multiple doses of MT-1186 200 mg suspension under fasted condition.	Matching Placebo (Multiple Doses Cohorts) Healthy Japanese male subjects receive multiple doses of matching placebo under fasted condition.
Maximum Plasma Concentration (Cmax) of Sulfate Conjugate Day 1	5481 ng/mL Standard Deviation 2337	9108 ng/mL Standard Deviation 2104	12190 ng/mL Standard Deviation 2087	7324 ng/mL Standard Deviation 743	14590 ng/mL Standard Deviation 2102	14080 ng/mL Standard Deviation 4787	2913 ng/mL Standard Deviation 870	11510 ng/mL Standard Deviation 2502	7318 ng/mL Standard Deviation 612	10830 ng/mL Standard Deviation 2346	—	—
Maximum Plasma Concentration (Cmax) of Sulfate Conjugate Day 5	—	—	—	—	—	—	—	—	7402 ng/mL Standard Deviation 954	11200 ng/mL Standard Deviation 1744	—	—

PRIMARY outcome

Timeframe: Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5

Population: The trial is divided into 2 phases (a single and multiple-dose). A single-dose study included 8 cohorts (total of 56 subjects), with 42 (6x7) subjects receiving MT-1186, and 14 (2x7) receiving the placebo. Multiple-dose study included 2 cohorts (total of 18 subjects), with 12 (6x2) receiving MT-1186, and 6 (3x2) receiving the placebo for 5 days. Since Cohort S3-1 and S3-2 are crossover cohort, the 5 subjects in Cohort S3-2 are overlapped (59 patients receiving MT-1186).

Outcome measures

Outcome measures
Measure	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 60 mg solution under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 120 mg suspension under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 200 mg with fasted condition under period 1.	A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2) n=5 Participants Healthy Japanese male subjects receive a single dose of MT-1186 200 mg under fed condition in period 2 with washout period at least 4-day.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 300 mg suspension with xanthan under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 300 mg suspension under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 30 mg solution under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7) n=6 Participants Healthy Caucasian male subjects receive a single dose of MT-1186 200 mg suspension under fasted condition.	Matching Placebo Under Fasted Condition (a Sngle Dose Cohorts) n=6 Participants Healthy Japanese/Caucasian male subjects receive a single dose of matching placebo.	Multiple Doses MT-1186 (Part 2, Cohort M1) n=6 Participants Healthy Japanese male subjects receive multiple doses of MT-1186 120 mg suspension under fasted condition.	Multiple Doses MT-1186 (Part 2, Cohort M2) Healthy Japanese male subjects receive multiple doses of MT-1186 200 mg suspension under fasted condition.	Matching Placebo (Multiple Doses Cohorts) Healthy Japanese male subjects receive multiple doses of matching placebo under fasted condition.
Maximum Plasma Concentration (Cmax) of Glucuronide Conjugate Day 1	1313 ng/mL Standard Deviation 378	2272 ng/mL Standard Deviation 279	3507 ng/mL Standard Deviation 158	1893 ng/mL Standard Deviation 358	5322 ng/mL Standard Deviation 958	3968 ng/mL Standard Deviation 912	750 ng/mL Standard Deviation 263	3361 ng/mL Standard Deviation 1183	2145 ng/mL Standard Deviation 356	3219 ng/mL Standard Deviation 666	—	—
Maximum Plasma Concentration (Cmax) of Glucuronide Conjugate Day 5	—	—	—	—	—	—	—	—	2209 ng/mL Standard Deviation 156	3439 ng/mL Standard Deviation 428	—	—

PRIMARY outcome

Timeframe: Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5

Population: The trial is divided into 2 phases (a single and multiple-dose). A single-dose study included 8 cohorts (S3-1 and S3-2 are crossover cohort, total of 56 subjects), with 42 (6x7) subjects receiving MT-1186, and 14 (2x7) receiving the placebo. Multiple-dose study included a total of 2 cohorts (total of 18 subjects), with 12 (6x2) receiving MT-1186, and 6 (3x2) receiving the placebo for 5 days.

Outcome measures

Outcome measures
Measure	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 60 mg solution under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 120 mg suspension under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1) Healthy Japanese male subjects receive a single dose of MT-1186 200 mg with fasted condition under period 1.	A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2) Healthy Japanese male subjects receive a single dose of MT-1186 200 mg under fed condition in period 2 with washout period at least 4-day.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4) Healthy Japanese male subjects receive a single dose of MT-1186 300 mg suspension with xanthan under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5) Healthy Japanese male subjects receive a single dose of MT-1186 300 mg suspension under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6) Healthy Japanese male subjects receive a single dose of MT-1186 30 mg solution under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7) Healthy Caucasian male subjects receive a single dose of MT-1186 200 mg suspension under fasted condition.	Matching Placebo Under Fasted Condition (a Sngle Dose Cohorts) Healthy Japanese/Caucasian male subjects receive a single dose of matching placebo.	Multiple Doses MT-1186 (Part 2, Cohort M1) Healthy Japanese male subjects receive multiple doses of MT-1186 120 mg suspension under fasted condition.	Multiple Doses MT-1186 (Part 2, Cohort M2) Healthy Japanese male subjects receive multiple doses of MT-1186 200 mg suspension under fasted condition.	Matching Placebo (Multiple Doses Cohorts) Healthy Japanese male subjects receive multiple doses of matching placebo under fasted condition.
Part 2: Minimum Plasma Concentration at Steady State (Ctrough, ss) Unchanged Edaravone	2.34 ng/mL Standard Deviation 0.30	3.79 ng/mL Standard Deviation 0.80	—	—	—	—	—	—	—	—	—	—
Part 2: Minimum Plasma Concentration at Steady State (Ctrough, ss) Sulfate conjugate	32.91 ng/mL Standard Deviation 9.01	49.98 ng/mL Standard Deviation 11.22	—	—	—	—	—	—	—	—	—	—
Part 2: Minimum Plasma Concentration at Steady State (Ctrough, ss) Glucuronide conjugate	2.69 ng/mL Standard Deviation 0.30	5.48 ng/mL Standard Deviation 1.90	—	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5

Population: The trial is divided into 2 phases (a single and multiple-dose). A single-dose study included 8 cohorts (total of 56 subjects), with 42 (6x7) subjects receiving MT-1186, and 14 (2x7) receiving the placebo. Multiple-dose study included 2 cohorts (total of 18 subjects), with 12 (6x2) receiving MT-1186, and 6 (3x2) receiving the placebo for 5 days. Since Cohort S3-1 and S3-2 are crossover cohort, the 5 subjects in Cohort S3-2 are overlapped (59 patients receiving MT-1186).

Outcome measures

Outcome measures
Measure	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 60 mg solution under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 120 mg suspension under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 200 mg with fasted condition under period 1.	A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2) n=5 Participants Healthy Japanese male subjects receive a single dose of MT-1186 200 mg under fed condition in period 2 with washout period at least 4-day.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 300 mg suspension with xanthan under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 300 mg suspension under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 30 mg solution under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7) n=6 Participants Healthy Caucasian male subjects receive a single dose of MT-1186 200 mg suspension under fasted condition.	Matching Placebo Under Fasted Condition (a Sngle Dose Cohorts) n=6 Participants Healthy Japanese/Caucasian male subjects receive a single dose of matching placebo.	Multiple Doses MT-1186 (Part 2, Cohort M1) n=6 Participants Healthy Japanese male subjects receive multiple doses of MT-1186 120 mg suspension under fasted condition.	Multiple Doses MT-1186 (Part 2, Cohort M2) Healthy Japanese male subjects receive multiple doses of MT-1186 200 mg suspension under fasted condition.	Matching Placebo (Multiple Doses Cohorts) Healthy Japanese male subjects receive multiple doses of matching placebo under fasted condition.
Time to Reach Maximum Plasma Concentration (Tmax) of Unchanged Edaravone Day 1	0.3 h Standard Deviation 0.1	0.4 h Standard Deviation 0.1	0.4 h Standard Deviation 0.1	1.4 h Standard Deviation 1.6	0.6 h Standard Deviation 0.3	0.8 h Standard Deviation 0.4	0.4 h Standard Deviation 0.1	0.6 h Standard Deviation 0.3	0.4 h Standard Deviation 0.1	0.4 h Standard Deviation 0.1	—	—
Time to Reach Maximum Plasma Concentration (Tmax) of Unchanged Edaravone Day 5	—	—	—	—	—	—	—	—	0.4 h Standard Deviation 0.1	0.4 h Standard Deviation 0.1	—	—

PRIMARY outcome

Timeframe: Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5

Population: The trial is divided into 2 phases (a single and multiple-dose). A single-dose study included 8 cohorts (total of 56 subjects), with 42 (6x7) subjects receiving MT-1186, and 14 (2x7) receiving the placebo. Multiple-dose study included 2 cohorts (total of 18 subjects), with 12 (6x2) receiving MT-1186, and 6 (3x2) receiving the placebo for 5 days. Since Cohort S3-1 and S3-2 are crossover cohort, the 5 subjects in Cohort S3-2 are overlapped (59 patients receiving MT-1186).

Outcome measures

Outcome measures
Measure	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 60 mg solution under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 120 mg suspension under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 200 mg with fasted condition under period 1.	A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2) n=5 Participants Healthy Japanese male subjects receive a single dose of MT-1186 200 mg under fed condition in period 2 with washout period at least 4-day.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 300 mg suspension with xanthan under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 300 mg suspension under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 30 mg solution under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7) n=6 Participants Healthy Caucasian male subjects receive a single dose of MT-1186 200 mg suspension under fasted condition.	Matching Placebo Under Fasted Condition (a Sngle Dose Cohorts) n=6 Participants Healthy Japanese/Caucasian male subjects receive a single dose of matching placebo.	Multiple Doses MT-1186 (Part 2, Cohort M1) n=6 Participants Healthy Japanese male subjects receive multiple doses of MT-1186 120 mg suspension under fasted condition.	Multiple Doses MT-1186 (Part 2, Cohort M2) Healthy Japanese male subjects receive multiple doses of MT-1186 200 mg suspension under fasted condition.	Matching Placebo (Multiple Doses Cohorts) Healthy Japanese male subjects receive multiple doses of matching placebo under fasted condition.
Time to Reach Maximum Plasma Concentration (Tmax) of Sulfate Conjugate Day 1	0.6 h Standard Deviation 0.2	0.8 h Standard Deviation 0.3	1.0 h Standard Deviation 0.0	1.3 h Standard Deviation 0.5	1.3 h Standard Deviation 0.3	1.4 h Standard Deviation 0.4	0.5 h Standard Deviation 0.3	0.9 h Standard Deviation 0.4	0.8 h Standard Deviation 0.3	0.9 h Standard Deviation 0.2	—	—
Time to Reach Maximum Plasma Concentration (Tmax) of Sulfate Conjugate Day 5	—	—	—	—	—	—	—	—	0.8 h Standard Deviation 0.3	0.8 h Standard Deviation 0.3	—	—

PRIMARY outcome

Timeframe: Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5

Population: The trial is divided into 2 phases (a single and multiple-dose). A single-dose study included 8 cohorts (total of 56 subjects), with 42 (6x7) subjects receiving MT-1186, and 14 (2x7) receiving the placebo. Multiple-dose study included 2 cohorts (total of 18 subjects), with 12 (6x2) receiving MT-1186, and 6 (3x2) receiving the placebo for 5 days. Since Cohort S3-1 and S3-2 are crossover cohort, the 5 subjects in Cohort S3-2 are overlapped (59 patients receiving MT-1186).

Outcome measures

Outcome measures
Measure	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 60 mg solution under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 120 mg suspension under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 200 mg with fasted condition under period 1.	A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2) n=5 Participants Healthy Japanese male subjects receive a single dose of MT-1186 200 mg under fed condition in period 2 with washout period at least 4-day.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 300 mg suspension with xanthan under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 300 mg suspension under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 30 mg solution under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7) n=6 Participants Healthy Caucasian male subjects receive a single dose of MT-1186 200 mg suspension under fasted condition.	Matching Placebo Under Fasted Condition (a Sngle Dose Cohorts) n=6 Participants Healthy Japanese/Caucasian male subjects receive a single dose of matching placebo.	Multiple Doses MT-1186 (Part 2, Cohort M1) n=6 Participants Healthy Japanese male subjects receive multiple doses of MT-1186 120 mg suspension under fasted condition.	Multiple Doses MT-1186 (Part 2, Cohort M2) Healthy Japanese male subjects receive multiple doses of MT-1186 200 mg suspension under fasted condition.	Matching Placebo (Multiple Doses Cohorts) Healthy Japanese male subjects receive multiple doses of matching placebo under fasted condition.
Time to Reach Maximum Plasma Concentration (Tmax) of Glucuronide Conjugate Day 1	0.5 h Standard Deviation 0.3	0.6 h Standard Deviation 0.2	0.6 h Standard Deviation 0.2	1.2 h Standard Deviation 0.6	1.0 h Standard Deviation 0.3	1.1 h Standard Deviation 0.4	0.5 h Standard Deviation 0.3	0.9 h Standard Deviation 0.4	0.7 h Standard Deviation 0.3	0.6 h Standard Deviation 0.2	—	—
Time to Reach Maximum Plasma Concentration (Tmax) of Glucuronide Conjugate Day 5	—	—	—	—	—	—	—	—	0.6 h Standard Deviation 0.2	0.7 h Standard Deviation 0.3	—	—

PRIMARY outcome

Timeframe: Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5

Population: The trial is divided into 2 phases (a single and multiple-dose). A single-dose study included 8 cohorts (total of 56 subjects), with 42 (6x7) subjects receiving MT-1186, and 14 (2x7) receiving the placebo. Multiple-dose study included 2 cohorts (total of 18 subjects), with 12 (6x2) receiving MT-1186, and 6 (3x2) receiving the placebo for 5 days. Since Cohort S3-1 and S3-2 are crossover cohort, the 5 subjects in Cohort S3-2 are overlapped (59 patients receiving MT-1186).

Outcome measures

Outcome measures
Measure	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 60 mg solution under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 120 mg suspension under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 200 mg with fasted condition under period 1.	A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2) n=5 Participants Healthy Japanese male subjects receive a single dose of MT-1186 200 mg under fed condition in period 2 with washout period at least 4-day.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 300 mg suspension with xanthan under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 300 mg suspension under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 30 mg solution under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7) n=6 Participants Healthy Caucasian male subjects receive a single dose of MT-1186 200 mg suspension under fasted condition.	Matching Placebo Under Fasted Condition (a Sngle Dose Cohorts) n=6 Participants Healthy Japanese/Caucasian male subjects receive a single dose of matching placebo.	Multiple Doses MT-1186 (Part 2, Cohort M1) n=6 Participants Healthy Japanese male subjects receive multiple doses of MT-1186 120 mg suspension under fasted condition.	Multiple Doses MT-1186 (Part 2, Cohort M2) Healthy Japanese male subjects receive multiple doses of MT-1186 200 mg suspension under fasted condition.	Matching Placebo (Multiple Doses Cohorts) Healthy Japanese male subjects receive multiple doses of matching placebo under fasted condition.
Terminal Elimination Half-life (t1/2) of Unchanged Edaravone Day 1	3.2 h Standard Deviation 0.9	5.1 h Standard Deviation 1.5	9.1 h Standard Deviation 2.4	5.2 h Standard Deviation 1.7	11.8 h Standard Deviation 4.	9.1 h Standard Deviation 3.3	2.4 h Standard Deviation 0.7	6.5 h Standard Deviation 1.7	4.6 h Standard Deviation 0.4	4.2 h Standard Deviation 0.2	—	—
Terminal Elimination Half-life (t1/2) of Unchanged Edaravone Day 5	—	—	—	—	—	—	—	—	8.7 h Standard Deviation 3.2	12.4 h Standard Deviation 1.9	—	—

PRIMARY outcome

Timeframe: Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5

Population: The trial is divided into 2 phases (a single and multiple-dose). A single-dose study included 8 cohorts (total of 56 subjects), with 42 (6x7) subjects receiving MT-1186, and 14 (2x7) receiving the placebo. Multiple-dose study included 2 cohorts (total of 18 subjects), with 12 (6x2) receiving MT-1186, and 6 (3x2) receiving the placebo for 5 days. Since Cohort S3-1 and S3-2 are crossover cohort, the 5 subjects in Cohort S3-2 are overlapped (59 patients receiving MT-1186).

Outcome measures

Outcome measures
Measure	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 60 mg solution under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 120 mg suspension under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 200 mg with fasted condition under period 1.	A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2) n=5 Participants Healthy Japanese male subjects receive a single dose of MT-1186 200 mg under fed condition in period 2 with washout period at least 4-day.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 300 mg suspension with xanthan under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 300 mg suspension under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 30 mg solution under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7) n=6 Participants Healthy Caucasian male subjects receive a single dose of MT-1186 200 mg suspension under fasted condition.	Matching Placebo Under Fasted Condition (a Sngle Dose Cohorts) n=6 Participants Healthy Japanese/Caucasian male subjects receive a single dose of matching placebo.	Multiple Doses MT-1186 (Part 2, Cohort M1) n=6 Participants Healthy Japanese male subjects receive multiple doses of MT-1186 120 mg suspension under fasted condition.	Multiple Doses MT-1186 (Part 2, Cohort M2) Healthy Japanese male subjects receive multiple doses of MT-1186 200 mg suspension under fasted condition.	Matching Placebo (Multiple Doses Cohorts) Healthy Japanese male subjects receive multiple doses of matching placebo under fasted condition.
Terminal Elimination Half-life (t1/2) of Sulfate Conjugate Day 1	7.9 h Standard Deviation 2.6	7.3 h Standard Deviation 2.6	5.9 h Standard Deviation 1.7	5.1 h Standard Deviation 1.3	6.0 h Standard Deviation 1.6	4.9 h Standard Deviation 0.3	5.2 h Standard Deviation 0.6	6.4 h Standard Deviation 2.6	3.7 h Standard Deviation 0.2	3.4 h Standard Deviation 0.3	—	—
Terminal Elimination Half-life (t1/2) of Sulfate Conjugate Day 5	—	—	—	—	—	—	—	—	6.2 h Standard Deviation 0.4	6.8 h Standard Deviation 1.0	—	—

PRIMARY outcome

Timeframe: Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5

Population: The trial is divided into 2 phases (a single and multiple-dose). A single-dose study included 8 cohorts (total of 56 subjects), with 42 (6x7) subjects receiving MT-1186, and 14 (2x7) receiving the placebo. Multiple-dose study included 2 cohorts (total of 18 subjects), with 12 (6x2) receiving MT-1186, and 6 (3x2) receiving the placebo for 5 days. Since Cohort S3-1 and S3-2 are crossover cohort, the 5 subjects in Cohort S3-2 are overlapped (59 patients receiving MT-1186).

Outcome measures

Outcome measures
Measure	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 60 mg solution under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 120 mg suspension under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 200 mg with fasted condition under period 1.	A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2) n=5 Participants Healthy Japanese male subjects receive a single dose of MT-1186 200 mg under fed condition in period 2 with washout period at least 4-day.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 300 mg suspension with xanthan under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 300 mg suspension under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 30 mg solution under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7) n=6 Participants Healthy Caucasian male subjects receive a single dose of MT-1186 200 mg suspension under fasted condition.	Matching Placebo Under Fasted Condition (a Sngle Dose Cohorts) n=6 Participants Healthy Japanese/Caucasian male subjects receive a single dose of matching placebo.	Multiple Doses MT-1186 (Part 2, Cohort M1) n=6 Participants Healthy Japanese male subjects receive multiple doses of MT-1186 120 mg suspension under fasted condition.	Multiple Doses MT-1186 (Part 2, Cohort M2) Healthy Japanese male subjects receive multiple doses of MT-1186 200 mg suspension under fasted condition.	Matching Placebo (Multiple Doses Cohorts) Healthy Japanese male subjects receive multiple doses of matching placebo under fasted condition.
Terminal Elimination Half-life (t1/2) of Glucuronide Conjugate Day 1	3.4 h Standard Deviation 1.1	3.2 h Standard Deviation 0.9	4.3 h Standard Deviation 0.7	3.8 h Standard Deviation 0.9	5.9 h Standard Deviation 1.4	4.8 h Standard Deviation 0.5	2.8 h Standard Deviation 0.9	4.7 h Standard Deviation 1.2	3.5 h Standard Deviation 0.2	3.2 h Standard Deviation 0.4	—	—
Terminal Elimination Half-life (t1/2) of Glucuronide Conjugate Day 5	—	—	—	—	—	—	—	—	3.9 h Standard Deviation 0.3	5.2 h Standard Deviation 2.0	—	—

PRIMARY outcome

Timeframe: Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5

Population: The trial is divided into 2 phases (a single and multiple-dose). A single-dose study included 8 cohorts (total of 56 subjects), with 42 (6x7) subjects receiving MT-1186, and 14 (2x7) receiving the placebo. Multiple-dose study included 2 cohorts (total of 18 subjects), with 12 (6x2) receiving MT-1186, and 6 (3x2) receiving the placebo for 5 days. Since Cohort S3-1 and S3-2 are crossover cohort, the 5 subjects in Cohort S3-2 are overlapped (59 patients receiving MT-1186).

Outcome measures

Outcome measures
Measure	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 60 mg solution under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 120 mg suspension under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 200 mg with fasted condition under period 1.	A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2) n=5 Participants Healthy Japanese male subjects receive a single dose of MT-1186 200 mg under fed condition in period 2 with washout period at least 4-day.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 300 mg suspension with xanthan under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 300 mg suspension under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 30 mg solution under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7) n=6 Participants Healthy Caucasian male subjects receive a single dose of MT-1186 200 mg suspension under fasted condition.	Matching Placebo Under Fasted Condition (a Sngle Dose Cohorts) n=6 Participants Healthy Japanese/Caucasian male subjects receive a single dose of matching placebo.	Multiple Doses MT-1186 (Part 2, Cohort M1) n=6 Participants Healthy Japanese male subjects receive multiple doses of MT-1186 120 mg suspension under fasted condition.	Multiple Doses MT-1186 (Part 2, Cohort M2) Healthy Japanese male subjects receive multiple doses of MT-1186 200 mg suspension under fasted condition.	Matching Placebo (Multiple Doses Cohorts) Healthy Japanese male subjects receive multiple doses of matching placebo under fasted condition.
Lambda-z of Unchanged Edaravone Day 1	0.23 1/h Standard Deviation 0.05	0.14 1/h Standard Deviation 0.03	0.08 1/h Standard Deviation 0.02	0.14 1/h Standard Deviation 0.04	0.07 1/h Standard Deviation 0.02	0.08 1/h Standard Deviation 0.02	0.31 1/h Standard Deviation 0.11	0.11 1/h Standard Deviation 0.03	0.15 1/h Standard Deviation 0.01	0.17 1/h Standard Deviation 0.01	—	—
Lambda-z of Unchanged Edaravone Day 5	—	—	—	—	—	—	—	—	0.09 1/h Standard Deviation 0.03	0.06 1/h Standard Deviation 0.01	—	—

PRIMARY outcome

Timeframe: Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5

Population: The trial is divided into 2 phases (a single and multiple-dose). A single-dose study included 8 cohorts (total of 56 subjects), with 42 (6x7) subjects receiving MT-1186, and 14 (2x7) receiving the placebo. Multiple-dose study included 2 cohorts (total of 18 subjects), with 12 (6x2) receiving MT-1186, and 6 (3x2) receiving the placebo for 5 days. Since Cohort S3-1 and S3-2 are crossover cohort, the 5 subjects in Cohort S3-2 are overlapped (59 patients receiving MT-1186).

Outcome measures

Outcome measures
Measure	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 60 mg solution under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 120 mg suspension under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 200 mg with fasted condition under period 1.	A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2) n=5 Participants Healthy Japanese male subjects receive a single dose of MT-1186 200 mg under fed condition in period 2 with washout period at least 4-day.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 300 mg suspension with xanthan under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 300 mg suspension under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 30 mg solution under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7) n=6 Participants Healthy Caucasian male subjects receive a single dose of MT-1186 200 mg suspension under fasted condition.	Matching Placebo Under Fasted Condition (a Sngle Dose Cohorts) n=6 Participants Healthy Japanese/Caucasian male subjects receive a single dose of matching placebo.	Multiple Doses MT-1186 (Part 2, Cohort M1) n=6 Participants Healthy Japanese male subjects receive multiple doses of MT-1186 120 mg suspension under fasted condition.	Multiple Doses MT-1186 (Part 2, Cohort M2) Healthy Japanese male subjects receive multiple doses of MT-1186 200 mg suspension under fasted condition.	Matching Placebo (Multiple Doses Cohorts) Healthy Japanese male subjects receive multiple doses of matching placebo under fasted condition.
Lambda-z of Sulfate Conjugate Day 1	0.10 1/h Standard Deviation 0.03	0.11 1/h Standard Deviation 0.04	0.12 1/h Standard Deviation 0.02	0.14 1/h Standard Deviation 0.03	0.12 1/h Standard Deviation 0.03	0.14 1/h Standard Deviation 0.01	0.14 1/h Standard Deviation 0.02	0.12 1/h Standard Deviation 0.03	0.19 1/h Standard Deviation 0.01	0.20 1/h Standard Deviation 0.02	—	—
Lambda-z of Sulfate Conjugate Day 5	—	—	—	—	—	—	—	—	0.11 1/h Standard Deviation 0.01	0.10 1/h Standard Deviation 0.02	—	—

PRIMARY outcome

Timeframe: Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5

Population: The trial is divided into 2 phases (a single and multiple-dose). A single-dose study included 8 cohorts (total of 56 subjects), with 42 (6x7) subjects receiving MT-1186, and 14 (2x7) receiving the placebo. Multiple-dose study included 2 cohorts (total of 18 subjects), with 12 (6x2) receiving MT-1186, and 6 (3x2) receiving the placebo for 5 days. Since Cohort S3-1 and S3-2 are crossover cohort, the 5 subjects in Cohort S3-2 are overlapped (59 patients receiving MT-1186).

Outcome measures

Outcome measures
Measure	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 60 mg solution under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 120 mg suspension under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 200 mg with fasted condition under period 1.	A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2) n=5 Participants Healthy Japanese male subjects receive a single dose of MT-1186 200 mg under fed condition in period 2 with washout period at least 4-day.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 300 mg suspension with xanthan under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 300 mg suspension under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 30 mg solution under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7) n=6 Participants Healthy Caucasian male subjects receive a single dose of MT-1186 200 mg suspension under fasted condition.	Matching Placebo Under Fasted Condition (a Sngle Dose Cohorts) n=6 Participants Healthy Japanese/Caucasian male subjects receive a single dose of matching placebo.	Multiple Doses MT-1186 (Part 2, Cohort M1) n=6 Participants Healthy Japanese male subjects receive multiple doses of MT-1186 120 mg suspension under fasted condition.	Multiple Doses MT-1186 (Part 2, Cohort M2) Healthy Japanese male subjects receive multiple doses of MT-1186 200 mg suspension under fasted condition.	Matching Placebo (Multiple Doses Cohorts) Healthy Japanese male subjects receive multiple doses of matching placebo under fasted condition.
Lambda-z of Glucuronide Conjugate Day 1	0.23 1/h Standard Deviation 0.09	0.23 1/h Standard Deviation 0.07	0.17 1/h Standard Deviation 0.03	0.19 1/h Standard Deviation 0.05	0.12 1/h Standard Deviation 0.02	0.15 1/h Standard Deviation 0.01	0.27 1/h Standard Deviation 0.07	0.16 1/h Standard Deviation 0.04	0.20 1/h Standard Deviation 0.01	0.22 1/h Standard Deviation 0.03	—	—
Lambda-z of Glucuronide Conjugate Day 5	—	—	—	—	—	—	—	—	0.18 1/h Standard Deviation 0.01	0.15 1/h Standard Deviation 0.05	—	—

PRIMARY outcome

Timeframe: Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5

Population: The trial is divided into 2 phases (a single and multiple-dose). A single-dose study included 8 cohorts (total of 56 subjects), with 42 (6x7) subjects receiving MT-1186, and 14 (2x7) receiving the placebo. Multiple-dose study included 2 cohorts (total of 18 subjects), with 12 (6x2) receiving MT-1186, and 6 (3x2) receiving the placebo for 5 days. Since Cohort S3-1 and S3-2 are crossover cohort, the 5 subjects in Cohort S3-2 are overlapped (59 patients receiving MT-1186).

Outcome measures

Outcome measures
Measure	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 60 mg solution under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 120 mg suspension under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 200 mg with fasted condition under period 1.	A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2) n=5 Participants Healthy Japanese male subjects receive a single dose of MT-1186 200 mg under fed condition in period 2 with washout period at least 4-day.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 300 mg suspension with xanthan under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 300 mg suspension under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 30 mg solution under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7) n=6 Participants Healthy Caucasian male subjects receive a single dose of MT-1186 200 mg suspension under fasted condition.	Matching Placebo Under Fasted Condition (a Sngle Dose Cohorts) n=6 Participants Healthy Japanese/Caucasian male subjects receive a single dose of matching placebo.	Multiple Doses MT-1186 (Part 2, Cohort M1) n=6 Participants Healthy Japanese male subjects receive multiple doses of MT-1186 120 mg suspension under fasted condition.	Multiple Doses MT-1186 (Part 2, Cohort M2) Healthy Japanese male subjects receive multiple doses of MT-1186 200 mg suspension under fasted condition.	Matching Placebo (Multiple Doses Cohorts) Healthy Japanese male subjects receive multiple doses of matching placebo under fasted condition.
Mean Residence Time (MRT) of Unchanged Edaravone Day 1	1.92 h Standard Deviation 0.46	2.07 h Standard Deviation 0.26	1.98 h Standard Deviation 0.15	3.41 h Standard Deviation 0.62	2.14 h Standard Deviation 0.20	2.42 h Standard Deviation 0.45	2.02 h Standard Deviation 0.20	2.02 h Standard Deviation 0.32	1.94 h Standard Deviation 0.15	1.90 h Standard Deviation 0.26	—	—
Mean Residence Time (MRT) of Unchanged Edaravone Day 5	—	—	—	—	—	—	—	—	2.17 h Standard Deviation 0.24	2.28 h Standard Deviation 0.37	—	—

PRIMARY outcome

Timeframe: Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5

Population: The trial is divided into 2 phases (a single and multiple-dose). A single-dose study included 8 cohorts (total of 56 subjects), with 42 (6x7) subjects receiving MT-1186, and 14 (2x7) receiving the placebo. Multiple-dose study included 2 cohorts (total of 18 subjects), with 12 (6x2) receiving MT-1186, and 6 (3x2) receiving the placebo for 5 days. Since Cohort S3-1 and S3-2 are crossover cohort, the 5 subjects in Cohort S3-2 are overlapped (59 patients receiving MT-1186).

Outcome measures

Outcome measures
Measure	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 60 mg solution under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 120 mg suspension under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 200 mg with fasted condition under period 1.	A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2) n=5 Participants Healthy Japanese male subjects receive a single dose of MT-1186 200 mg under fed condition in period 2 with washout period at least 4-day.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 300 mg suspension with xanthan under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 300 mg suspension under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 30 mg solution under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7) n=6 Participants Healthy Caucasian male subjects receive a single dose of MT-1186 200 mg suspension under fasted condition.	Matching Placebo Under Fasted Condition (a Sngle Dose Cohorts) n=6 Participants Healthy Japanese/Caucasian male subjects receive a single dose of matching placebo.	Multiple Doses MT-1186 (Part 2, Cohort M1) n=6 Participants Healthy Japanese male subjects receive multiple doses of MT-1186 120 mg suspension under fasted condition.	Multiple Doses MT-1186 (Part 2, Cohort M2) Healthy Japanese male subjects receive multiple doses of MT-1186 200 mg suspension under fasted condition.	Matching Placebo (Multiple Doses Cohorts) Healthy Japanese male subjects receive multiple doses of matching placebo under fasted condition.
Apparent Total Clearance (CL/F) of Unchanged Edaravone Day 1	79.77 L/h Standard Deviation 26.21	60.29 L/h Standard Deviation 22.90	32.73 L/h Standard Deviation 6.42	87.07 L/h Standard Deviation 22.96	26.42 L/h Standard Deviation 2.30	36.11 L/h Standard Deviation 13.62	119.41 L/h Standard Deviation 43.64	46.72 L/h Standard Deviation 20.27	64.51 L/h Standard Deviation 11.64	53.40 L/h Standard Deviation 20.46	—	—
Apparent Total Clearance (CL/F) of Unchanged Edaravone Day 5	—	—	—	—	—	—	—	—	57.64 L/h Standard Deviation 14.54	50.74 L/h Standard Deviation 18.08	—	—

PRIMARY outcome

Timeframe: Part 1: Pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs post-dose, Part 2: Day 1 and 5 at pre-dose, 0.25, 0.5, 1.5, 2, 4, 6, 8, 12 hrs post-dose; Day 2 to 4 at pre-dose; Day 6 at 24 hrs post-dose on Day 5; Day 7 at 48 hrs post-dose on Day 5

Population: The trial is divided into 2 phases (a single and multiple-dose). A single-dose study included 8 cohorts (total of 56 subjects), with 42 (6x7) subjects receiving MT-1186, and 14 (2x7) receiving the placebo. Multiple-dose study included 2 cohorts (total of 18 subjects), with 12 (6x2) receiving MT-1186, and 6 (3x2) receiving the placebo for 5 days. Since Cohort S3-1 and S3-2 are crossover cohort, the 5 subjects in Cohort S3-2 are overlapped (59 patients receiving MT-1186).

Outcome measures

Outcome measures
Measure	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 60 mg solution under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 120 mg suspension under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 200 mg with fasted condition under period 1.	A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2) n=5 Participants Healthy Japanese male subjects receive a single dose of MT-1186 200 mg under fed condition in period 2 with washout period at least 4-day.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 300 mg suspension with xanthan under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 300 mg suspension under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 30 mg solution under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7) n=6 Participants Healthy Caucasian male subjects receive a single dose of MT-1186 200 mg suspension under fasted condition.	Matching Placebo Under Fasted Condition (a Sngle Dose Cohorts) n=6 Participants Healthy Japanese/Caucasian male subjects receive a single dose of matching placebo.	Multiple Doses MT-1186 (Part 2, Cohort M1) n=6 Participants Healthy Japanese male subjects receive multiple doses of MT-1186 120 mg suspension under fasted condition.	Multiple Doses MT-1186 (Part 2, Cohort M2) Healthy Japanese male subjects receive multiple doses of MT-1186 200 mg suspension under fasted condition.	Matching Placebo (Multiple Doses Cohorts) Healthy Japanese male subjects receive multiple doses of matching placebo under fasted condition.
Apparent Distribution Volume at Elimination Phase (Vz/F) and Apparent Distribution Volume at Steady State (Vss/F) of Unchanged Edaravone Vz/F (Part 1), Vss/F (Part 2): Day1	348.98 L Standard Deviation 87.82	422.67 L Standard Deviation 126.97	426.49 L Standard Deviation 130.84	620.73 L Standard Deviation 139.24	457.99 L Standard Deviation 188.01	457.37 L Standard Deviation 175.69	384.51 L Standard Deviation 96.92	408.95 L Standard Deviation 121.29	126.41 L Standard Deviation 29.65	105.90 L Standard Deviation 57.04	—	—
Apparent Distribution Volume at Elimination Phase (Vz/F) and Apparent Distribution Volume at Steady State (Vss/F) of Unchanged Edaravone Vss/F (only Part 2): Day 5	—	—	—	—	—	—	—	—	125.94 L Standard Deviation 40.36	121.32 L Standard Deviation 66.83	—	—

SECONDARY outcome

Timeframe: 0.75, 0.5, and 0.25 hours pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, and 48 hours post-dose.

Population: Pharmacodynamic data were collected in Cohort S4, S5 and S6 with 18 (6x3 subjects receiving MT-1186), and 6 (2x3) receiving the placebo of Part 1.

Holter ECG data were recorded in part 1, Cohorts S4, S5, and S6. Baseline is calculated as average HR from 0.75, 0.5, and 0.25 hours pre-dose.

Outcome measures

Outcome measures
Measure	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 60 mg solution under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 120 mg suspension under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 200 mg with fasted condition under period 1.	A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 200 mg under fed condition in period 2 with washout period at least 4-day.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4) Healthy Japanese male subjects receive a single dose of MT-1186 300 mg suspension with xanthan under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5) Healthy Japanese male subjects receive a single dose of MT-1186 300 mg suspension under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6) Healthy Japanese male subjects receive a single dose of MT-1186 30 mg solution under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7) Healthy Caucasian male subjects receive a single dose of MT-1186 200 mg suspension under fasted condition.	Matching Placebo Under Fasted Condition (a Sngle Dose Cohorts) Healthy Japanese/Caucasian male subjects receive a single dose of matching placebo.	Multiple Doses MT-1186 (Part 2, Cohort M1) Healthy Japanese male subjects receive multiple doses of MT-1186 120 mg suspension under fasted condition.	Multiple Doses MT-1186 (Part 2, Cohort M2) Healthy Japanese male subjects receive multiple doses of MT-1186 200 mg suspension under fasted condition.	Matching Placebo (Multiple Doses Cohorts) Healthy Japanese male subjects receive multiple doses of matching placebo under fasted condition.
Change of Heart Rate (HR) From Baseline 0.25h	1.8 bpm Standard Error 0.91	-1.2 bpm Standard Error 0.91	1.8 bpm Standard Error 0.96	-0.2 bpm Standard Error 0.92	—	—	—	—	—	—	—	—
Change of Heart Rate (HR) From Baseline 0.5h	-0.2 bpm Standard Error 1.01	0.2 bpm Standard Error 1.01	1.3 bpm Standard Error 1.06	1.2 bpm Standard Error 1.02	—	—	—	—	—	—	—	—
Change of Heart Rate (HR) From Baseline 1h	-0.1 bpm Standard Error 1.28	-1.7 bpm Standard Error 1.28	0.2 bpm Standard Error 1.34	-0.2 bpm Standard Error 1.29	—	—	—	—	—	—	—	—
Change of Heart Rate (HR) From Baseline 1.5h	-1.2 bpm Standard Error 1.00	-0.3 bpm Standard Error 1.00	0.2 bpm Standard Error 1.04	-0.1 bpm Standard Error 1.01	—	—	—	—	—	—	—	—
Change of Heart Rate (HR) From Baseline 2h	-0.1 bpm Standard Error 0.95	0.4 bpm Standard Error 0.95	0.9 bpm Standard Error 0.99	-0.1 bpm Standard Error 0.96	—	—	—	—	—	—	—	—
Change of Heart Rate (HR) From Baseline 4h	-0.7 bpm Standard Error 1.36	-1.6 bpm Standard Error 1.36	-0.1 bpm Standard Error 1.42	-1.5 bpm Standard Error 1.37	—	—	—	—	—	—	—	—
Change of Heart Rate (HR) From Baseline 6h	3.2 bpm Standard Error 1.88	6.4 bpm Standard Error 1.87	3.8 bpm Standard Error 1.96	3.8 bpm Standard Error 1.89	—	—	—	—	—	—	—	—
Change of Heart Rate (HR) From Baseline 8h	4.4 bpm Standard Error 1.72	4.1 bpm Standard Error 1.72	6.2 bpm Standard Error 1.80	3.4 bpm Standard Error 1.74	—	—	—	—	—	—	—	—
Change of Heart Rate (HR) From Baseline 12h	1.9 bpm Standard Error 2.07	10.1 bpm Standard Error 2.07	7.6 bpm Standard Error 2.16	4.6 bpm Standard Error 2.09	—	—	—	—	—	—	—	—
Change of Heart Rate (HR) From Baseline 24h	1.3 bpm Standard Error 1.54	1.7 bpm Standard Error 1.54	2.2 bpm Standard Error 1.61	-1 bpm Standard Error 1.55	—	—	—	—	—	—	—	—
Change of Heart Rate (HR) From Baseline 36h	8.1 bpm Standard Error 3.07	9.9 bpm Standard Error 3.06	13.2 bpm Standard Error 3.21	5.7 bpm Standard Error 3.10	—	—	—	—	—	—	—	—
Change of Heart Rate (HR) From Baseline 48h	4.3 bpm Standard Error 2.51	8.2 bpm Standard Error 2.51	8.4 bpm Standard Error 2.62	2.4 bpm Standard Error 2.53	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: 0.75, 0.5, and 0.25 hours pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, and 48 hours post-dose.

Population: Pharmacodynamic data were collected in Cohort S4, S5 and S6 with 18 (6x3 subjects receiving MT-1186), and 6 (2x3) receiving the placebo of Part 1.

Holter ECG data were recorded in part 1, Cohorts S4, S5, and S6. Baseline is calculated as average HR from 0.75, 0.5, and 0.25 hours pre-dose.

Outcome measures

Outcome measures
Measure	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 60 mg solution under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 120 mg suspension under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 200 mg with fasted condition under period 1.	A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 200 mg under fed condition in period 2 with washout period at least 4-day.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4) Healthy Japanese male subjects receive a single dose of MT-1186 300 mg suspension with xanthan under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5) Healthy Japanese male subjects receive a single dose of MT-1186 300 mg suspension under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6) Healthy Japanese male subjects receive a single dose of MT-1186 30 mg solution under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7) Healthy Caucasian male subjects receive a single dose of MT-1186 200 mg suspension under fasted condition.	Matching Placebo Under Fasted Condition (a Sngle Dose Cohorts) Healthy Japanese/Caucasian male subjects receive a single dose of matching placebo.	Multiple Doses MT-1186 (Part 2, Cohort M1) Healthy Japanese male subjects receive multiple doses of MT-1186 120 mg suspension under fasted condition.	Multiple Doses MT-1186 (Part 2, Cohort M2) Healthy Japanese male subjects receive multiple doses of MT-1186 200 mg suspension under fasted condition.	Matching Placebo (Multiple Doses Cohorts) Healthy Japanese male subjects receive multiple doses of matching placebo under fasted condition.
Change of PR Interval (PR) From Baseline 0.25h	-6.8 msec Standard Error 1.91	-3.3 msec Standard Error 1.99	-5.7 msec Standard Error 1.92	-4.5 msec Standard Error 2.06	—	—	—	—	—	—	—	—
Change of PR Interval (PR) From Baseline 0.5h	-4.2 msec Standard Error 1.35	0.1 msec Standard Error 1.40	-2.4 msec Standard Error 1.36	-3.4 msec Standard Error 1.45	—	—	—	—	—	—	—	—
Change of PR Interval (PR) From Baseline 1h	-4.2 msec Standard Error 1.68	2.1 msec Standard Error 1.74	-4.0 msec Standard Error 1.68	-4.7 msec Standard Error 1.80	—	—	—	—	—	—	—	—
Change of PR Interval (PR) From Baseline 1.5h	-5.2 msec Standard Error 2.23	0.0 msec Standard Error 2.31	-4.8 msec Standard Error 2.24	-5.3 msec Standard Error 2.40	—	—	—	—	—	—	—	—
Change of PR Interval (PR) From Baseline 2h	-5.9 msec Standard Error 1.90	-0.8 msec Standard Error 1.97	-4.5 msec Standard Error 1.91	-5.9 msec Standard Error 2.05	—	—	—	—	—	—	—	—
Change of PR Interval (PR) From Baseline 4h	-3.0 msec Standard Error 2.64	-3.0 msec Standard Error 2.74	-5.3 msec Standard Error 2.66	-5.4 msec Standard Error 2.85	—	—	—	—	—	—	—	—
Change of PR Interval (PR) From Baseline 6h	-5.5 msec Standard Error 1.91	-9.6 msec Standard Error 1.98	-6.3 msec Standard Error 1.92	-6.6 msec Standard Error 2.06	—	—	—	—	—	—	—	—
Change of PR Interval (PR) From Baseline 8h	-11.6 msec Standard Error 2.60	-9.0 msec Standard Error 2.70	-9.9 msec Standard Error 2.62	-11.9 msec Standard Error 2.80	—	—	—	—	—	—	—	—
Change of PR Interval (PR) From Baseline 12h	-6.6 msec Standard Error 3.91	-12.0 msec Standard Error 4.06	-9.0 msec Standard Error 3.93	-11.8 msec Standard Error 4.21	—	—	—	—	—	—	—	—
Change of PR Interval (PR) From Baseline 24h	-2.1 msec Standard Error 2.62	-1.6 msec Standard Error 2.72	-8.9 msec Standard Error 2.63	-1.1 msec Standard Error 2.82	—	—	—	—	—	—	—	—
Change of PR Interval (PR) From Baseline 36h	-5.7 msec Standard Error 3.77	-6.8 msec Standard Error 3.91	-6.2 msec Standard Error 3.78	-9.5 msec Standard Error 4.06	—	—	—	—	—	—	—	—
Change of PR Interval (PR) From Baseline 48h	-3.3 msec Standard Error 2.63	0.6 msec Standard Error 2.73	-3.2 msec Standard Error 2.64	-5.4 msec Standard Error 2.83	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: 0.75, 0.5, and 0.25 hours pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, and 48 hours post-dose.

Population: Pharmacodynamic data were collected in Cohort S4, S5 and S6 with 18 (6x3 subjects receiving MT-1186), and 6 (2x3) receiving the placebo of Part 1.

Holter ECG data were recorded in part 1, Cohorts S4, S5, and S6. Baseline is calculated as average HR from 0.75, 0.5, and 0.25 hours pre-dose.

Outcome measures

Outcome measures
Measure	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 60 mg solution under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 120 mg suspension under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 200 mg with fasted condition under period 1.	A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 200 mg under fed condition in period 2 with washout period at least 4-day.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4) Healthy Japanese male subjects receive a single dose of MT-1186 300 mg suspension with xanthan under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5) Healthy Japanese male subjects receive a single dose of MT-1186 300 mg suspension under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6) Healthy Japanese male subjects receive a single dose of MT-1186 30 mg solution under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7) Healthy Caucasian male subjects receive a single dose of MT-1186 200 mg suspension under fasted condition.	Matching Placebo Under Fasted Condition (a Sngle Dose Cohorts) Healthy Japanese/Caucasian male subjects receive a single dose of matching placebo.	Multiple Doses MT-1186 (Part 2, Cohort M1) Healthy Japanese male subjects receive multiple doses of MT-1186 120 mg suspension under fasted condition.	Multiple Doses MT-1186 (Part 2, Cohort M2) Healthy Japanese male subjects receive multiple doses of MT-1186 200 mg suspension under fasted condition.	Matching Placebo (Multiple Doses Cohorts) Healthy Japanese male subjects receive multiple doses of matching placebo under fasted condition.
Change of QTcF Interval (QTcF) From Baseline 0.25h	2.0 msec Standard Error 1.60	0.7 msec Standard Error 1.60	1.6 msec Standard Error 1.63	0.8 msec Standard Error 1.71	—	—	—	—	—	—	—	—
Change of QTcF Interval (QTcF) From Baseline 0.5h	-2.2 msec Standard Error 1.32	1.1 msec Standard Error 1.31	-3.8 msec Standard Error 1.34	-4.9 msec Standard Error 1.41	—	—	—	—	—	—	—	—
Change of QTcF Interval (QTcF) From Baseline 1h	0.3 msec Standard Error 2.02	-0.1 msec Standard Error 2.02	-4.7 msec Standard Error 2.06	0.5 msec Standard Error 2.17	—	—	—	—	—	—	—	—
Change of QTcF Interval (QTcF) From Baseline 1.5h	-5.2 msec Standard Error 2.23	2.7 msec Standard Error 1.68	-1.9 msec Standard Error 1.71	-5.3 msec Standard Error 2.40	—	—	—	—	—	—	—	—
Change of QTcF Interval (QTcF) From Baseline 2h	1.2 msec Standard Error 1.68	1.5 msec Standard Error 2.34	-5.1 msec Standard Error 2.39	0.8 msec Standard Error 1.80	—	—	—	—	—	—	—	—
Change of QTcF Interval (QTcF) From Baseline 4h	2.3 msec Standard Error 2.85	-0.9 msec Standard Error 2.85	1.4 msec Standard Error 2.90	0.7 msec Standard Error 3.06	—	—	—	—	—	—	—	—
Change of QTcF Interval (QTcF) From Baseline 6h	-5.7 msec Standard Error 2.96	-2.9 msec Standard Error 2.96	-7.6 msec Standard Error 3.01	-2.4 msec Standard Error 3.18	—	—	—	—	—	—	—	—
Change of QTcF Interval (QTcF) From Baseline 8h	-5.3 msec Standard Error 2.62	-2.9 msec Standard Error 2.62	-7.0 msec Standard Error 2.66	-6.9 msec Standard Error 2.81	—	—	—	—	—	—	—	—
Change of QTcF Interval (QTcF) From Baseline 12h	-2.3 msec Standard Error 2.42	-4.0 msec Standard Error 2.42	-3.1 msec Standard Error 2.47	-3.3 msec Standard Error 2.6	—	—	—	—	—	—	—	—
Change of QTcF Interval (QTcF) From Baseline 24h	2.0 msec Standard Error 2.42	-1.2 msec Standard Error 2.42	-5.7 msec Standard Error 2.46	-3.1 msec Standard Error 2.60	—	—	—	—	—	—	—	—
Change of QTcF Interval (QTcF) From Baseline 36h	-3.0 msec Standard Error 2.96	-5.0 msec Standard Error 2.96	-5.1 msec Standard Error 3.01	-1.4 msec Standard Error 3.18	—	—	—	—	—	—	—	—
Change of QTcF Interval (QTcF) From Baseline 48h	-1.0 msec Standard Error 3.22	-1.5 msec Standard Error 3.22	-4.4 msec Standard Error 3.28	-0.1 msec Standard Error 3.46	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: 0.75, 0.5, and 0.25 hours pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, and 48 hours post-dose.

Population: Pharmacodynamic data were collected in Cohort S4, S5 and S6 with 18 (6x3 subjects receiving MT-1186), and 6 (2x3) receiving the placebo of Part 1.

Holter ECG data were recorded in part 1, Cohorts S4, S5, and S6.

Outcome measures

Outcome measures
Measure	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S1) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 60 mg solution under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S2) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 120 mg suspension under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S3-1) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 200 mg with fasted condition under period 1.	A Single Dose MT-1186 Under Fed Condition(Part 1, Cohort S3-2) n=6 Participants Healthy Japanese male subjects receive a single dose of MT-1186 200 mg under fed condition in period 2 with washout period at least 4-day.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S4) Healthy Japanese male subjects receive a single dose of MT-1186 300 mg suspension with xanthan under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S5) Healthy Japanese male subjects receive a single dose of MT-1186 300 mg suspension under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S6) Healthy Japanese male subjects receive a single dose of MT-1186 30 mg solution under fasted condition.	A Single Dose MT-1186 Under Fasted Condition (Part 1, Cohort S7) Healthy Caucasian male subjects receive a single dose of MT-1186 200 mg suspension under fasted condition.	Matching Placebo Under Fasted Condition (a Sngle Dose Cohorts) Healthy Japanese/Caucasian male subjects receive a single dose of matching placebo.	Multiple Doses MT-1186 (Part 2, Cohort M1) Healthy Japanese male subjects receive multiple doses of MT-1186 120 mg suspension under fasted condition.	Multiple Doses MT-1186 (Part 2, Cohort M2) Healthy Japanese male subjects receive multiple doses of MT-1186 200 mg suspension under fasted condition.	Matching Placebo (Multiple Doses Cohorts) Healthy Japanese male subjects receive multiple doses of matching placebo under fasted condition.
Change of QRS Duration (QRS) From Baseline 0.25h	-0.7 msec Standard Error 0.85	-0.4 msec Standard Error 0.84	0.4 msec Standard Error 0.87	-2.0 msec Standard Error 0.88	—	—	—	—	—	—	—	—
Change of QRS Duration (QRS) From Baseline 0.5h	-0.3 msec Standard Error 0.77	-0.8 msec Standard Error 0.77	-0.5 msec Standard Error 0.80	-1.6 msec Standard Error 0.80	—	—	—	—	—	—	—	—
Change of QRS Duration (QRS) From Baseline 1h	-0.3 msec Standard Error 0.70	-1.5 msec Standard Error 0.69	0.5 msec Standard Error 0.72	-1.4 msec Standard Error 0.72	—	—	—	—	—	—	—	—
Change of QRS Duration (QRS) From Baseline 1.5h	-0.4 msec Standard Error 0.70	-0.7 msec Standard Error 0.80	0.4 msec Standard Error 0.83	-1.4 msec Standard Error 0.72	—	—	—	—	—	—	—	—
Change of QRS Duration (QRS) From Baseline 2h	-1.5 msec Standard Error 0.98	-0.5 msec Standard Error 0.98	0.2 msec Standard Error 1.01	-2.7 msec Standard Error 1.02	—	—	—	—	—	—	—	—
Change of QRS Duration (QRS) From Baseline 4h	-0.5 msec Standard Error 1.36	-2.1 msec Standard Error 1.36	-0.4 msec Standard Error 1.41	-0.5 msec Standard Error 1.42	—	—	—	—	—	—	—	—
Change of QRS Duration (QRS) From Baseline 6h	-0.3 msec Standard Error 1.31	1.1 msec Standard Error 1.31	-0.8 msec Standard Error 1.36	0.7 msec Standard Error 1.37	—	—	—	—	—	—	—	—
Change of QRS Duration (QRS) From Baseline 8h	-1.2 msec Standard Error 1.50	0.0 msec Standard Error 1.50	-2.4 msec Standard Error 1.55	-1.3 msec Standard Error 1.57	—	—	—	—	—	—	—	—
Change of QRS Duration (QRS) From Baseline 12h	0.4 msec Standard Error 1.71	-2.1 msec Standard Error 1.71	-2.0 msec Standard Error 1.77	0.0 msec Standard Error 1.78	—	—	—	—	—	—	—	—
Change of QRS Duration (QRS) From Baseline 24h	-0.9 msec Standard Error 1.26	-2.2 msec Standard Error 1.25	-1.4 msec Standard Error 1.30	-1.2 msec Standard Error 1.31	—	—	—	—	—	—	—	—
Change of QRS Duration (QRS) From Baseline 36h	-0.2 msec Standard Error 1.76	-1.5 msec Standard Error 1.75	-2.4 msec Standard Error 1.81	0.4 msec Standard Error 1.83	—	—	—	—	—	—	—	—
Change of QRS Duration (QRS) From Baseline 48h	-1.7 msec Standard Error 1.18	-1.5 msec Standard Error 1.17	-1.4 msec Standard Error 1.22	-0.1 msec Standard Error 1.23	—	—	—	—	—	—	—	—

Deaths: 0 deaths

Matching Placebo (Multiple Doses Cohorts)

Serious events: 0 serious events

Other events: 1 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure	A Single Dose MT-1186 (Part 1, Cohort S1) n=6 participants at risk Healthy Japanese male subjects receive a single dose of MT-1186 60 mg solution.	A Single Dose MT-1186 (Part 1, Cohort S2) n=6 participants at risk Healthy Japanese male subjects receive a single dose of MT-1186 120 mg suspension.	A Single Dose MT-1186 (Part 1, Cohort S3) n=6 participants at risk Healthy Japanese male subjects receive a single dose of MT-1186 200 mg under fasted condition in period 1, and fed condition in period 2 with washout period at least 4-day.	A Single Dose MT-1186 (Part 1, Cohort S4) n=6 participants at risk Healthy Japanese male subjects receive a single dose of MT-1186 300 mg suspension with xanthan.	A Single Dose MT-1186 (Part 1, Cohort S5) n=6 participants at risk Healthy Japanese male subjects receive a single dose of MT-1186 300 mg suspension.	A Single Dose MT-1186 (Part 1, Cohort S6) n=6 participants at risk Healthy Japanese male subjects receive a single dose of MT-1186 30 mg suspension.	A Single Dose MT-1186 (Part 1, Cohort S7) n=6 participants at risk Healthy Caucasian male subjects receive a single dose of MT-1186 200 mg suspension.	Matching Placebo (a Single Dose Cohorts) n=14 participants at risk Healthy Japanese/Caucasian male subjects receive a single dose of matching placebo.	Multiple Doses MT-1186 (Part 2, Cohort M1) n=6 participants at risk Healthy Japanese male subjects receive multiple doses of MT-1186 120 mg suspension.	Multiple Doses MT-1186 (Part 2, Cohort M2) n=6 participants at risk Healthy Japanese male subjects receive multiple doses of MT-1186 200 mg suspension.	Matching Placebo (Multiple Doses Cohorts) n=6 participants at risk Healthy Japanese male subjects receive multiple doses of matching placebo.
Infections and infestations Conjunctivitis	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	16.7% 1/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/14 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2
Infections and infestations Nasopharyngitis	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	16.7% 1/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/14 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2
Infections and infestations Pharyngitis	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	7.1% 1/14 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2
Nervous system disorders Dizziness postural	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/14 • 8 days in part 1, 12 days in part 2	16.7% 1/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2
Nervous system disorders Headache	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	33.3% 2/6 • 8 days in part 1, 12 days in part 2	0.00% 0/14 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	16.7% 1/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2
Nervous system disorders Presyncope	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	16.7% 1/6 • 8 days in part 1, 12 days in part 2	0.00% 0/14 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2
General disorders Pyrexia	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	16.7% 1/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/14 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2
Gastrointestinal disorders Enterocolitis	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/14 • 8 days in part 1, 12 days in part 2	16.7% 1/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2
Hepatobiliary disorders Hepatic function abnormal	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/14 • 8 days in part 1, 12 days in part 2	16.7% 1/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2
Skin and subcutaneous tissue disorders Rash pruritic	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/14 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	16.7% 1/6 • 8 days in part 1, 12 days in part 2
Investigations Blood creatine phosphokinase increased	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	16.7% 1/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/14 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	16.7% 1/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2
Investigations Blood glucose increased	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	16.7% 1/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/14 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2
Investigations Blood uric acid increased	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	7.1% 1/14 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2
Investigations Blood urine present	0.00% 0/6 • 8 days in part 1, 12 days in part 2	16.7% 1/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/14 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2
Investigations White blood cell count increased	0.00% 0/6 • 8 days in part 1, 12 days in part 2	16.7% 1/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	16.7% 1/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/14 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2
Investigations Protein urine present	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/14 • 8 days in part 1, 12 days in part 2	16.7% 1/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2	0.00% 0/6 • 8 days in part 1, 12 days in part 2

Additional Information

Clinical Trials, Information Desk

Tanabe Pharma Corporation

Phone: Please e-mail

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place

Restriction type: OTHER